logo

FENC

Fennec Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
2.35 / 10
Underperform

FENC's fundamentals score just 2.35/10, underscoring structural weaknesses. Key red flags include a negative Asset-MV (-0.50) and Cash-MV (-1.95) ranking in the least favorable quartiles, alongside a Net profit / Total profit (%) of 100% indicating potential data quirks or one-off items. Although Profit-MV (0.46) and Gross profit margin (%) (93.5%) look supportive, they are outweighed by downside factors. The PB-ROE sits at 4.20, placing the stock in Group 4 with a modest quality score of 2/3. Overall, the balance of evidence points to a defensive stance until profitability and asset efficiency improve.

Fundamental(2.35)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-1.26
Score1/3
Weight15.42%
1M Return5.20%
Inventory turnover ratio
Value1.13
Score2/3
Weight-5.85%
1M Return-2.63%
Gross profit margin (%)
Value93.52
Score2/3
Weight3.82%
1M Return1.47%
Profit-MV
Value0.46
Score2/3
Weight23.09%
1M Return7.79%
PB-ROE
Value4.20
Score2/3
Weight32.41%
1M Return10.68%
Current assets turnover ratio
Value0.68
Score1/3
Weight-1.16%
1M Return-0.48%
Fixed assets turnover ratio
Value7979.42
Score3/3
Weight1.97%
1M Return0.86%
Asset-MV
Value-0.50
Score0/3
Weight7.89%
1M Return2.94%
Cash-MV
Value-1.95
Score2/3
Weight23.12%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.68%
1M Return-0.30%
Is FENC undervalued or overvalued?
  • FENC scores 2.35/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -17.89% net margin, -37.80 P/E ratio, -58.39 P/B ratio, and -550.00% earnings growth, these metrics solidify its Underperform investment rating.